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Abstract
The World Health Organization (WHO) recommends
that the cost-effectiveness (CE) of introducing new
vaccines be considered before such a programme is
implemented. However, in low- and middle-income
countries (LMICs), it is often challenging to perform
and interpret the results of model-based economic
appraisals of vaccines that benefit from locally
relevant data. As a result, WHO embarked on a series
of consultations to assess economic analytical tools to
support vaccine introduction decisions for
pneumococcal, rotavirus and human papillomavirus
vaccines. The objectives of these assessments are to
provide decision makers with a menu of existing CE
tools for vaccines and their characteristics rather than
to endorse the use of a single tool. The outcome will
provide policy makers in LMICs with information
about the feasibility of applying these models to
inform their own decision making. We argue that if
models and CE analyses are used to inform decisions,
they ought to be critically appraised beforehand,
including a transparent evaluation of their structure,
assumptions and data sources (in isolation or in
comparison to similar tools), so that decision makers
can use them while being fully aware of their
robustness and limitations.
Background
Over the next decade, several new vaccines will be con-
sidered for universal use against infectious diseases of
major public health importance. Public health decision
makers will need to make choices between vaccines and
among various health interventions. New vaccines are
more expensive than the traditional dollars-and-cents
vaccine costs, while countries increasingly have to bear
the full cost of vaccination programmes. Because not all
evidence is available to explore the impact of interven-
tions under different scenarios, cost-effectiveness ana-
lyses (CEAs) of vaccination programmes tend to be
based on mathematical modelling, which should yield a
framework and help synthesize information from many
sources and also help extrapolate data beyond available
data (for example, clinical trials). Given the complexity
and the importance of these tools, and to accurately
inform vaccine policy makers at the country level, a cri-
tical appraisal of these tools’ robustness and limitations
as well as of the generalizability of model estimates to
local contexts needs to be conducted and documented
before results are accepted.
A recent systematic literature review showed that
cost-effectiveness (CE) has become an increasingly
important factor for stakeholders who need to make
decisions about adding a new vaccine into national
immunization programmes versus alternative uses of
resources [1]. However, the same study also pointed out
t h a tt h em a j o r i t yo ft h e s es t u d i e sw e r ed o n ei nh i g h -
income countries, while in low- and middle-income
countries (LMICs), where fewer studies are performed,
economic evaluations have a more limited role in the
decision-making process.
The need for increased guidance on CE was clearly
identified in a stakeholder review conducted on the
World Health Organization’s (WHO’s) normative role in
immunization [2]. Country-level decision makers, parti-
cularly those from LMICs, discussed the lack of gui-
dance on the criteria used to assess the model structure,
assumptions, robustness and limitations of economic
decision-making tools [3]. As a response to these needs,
WHO embarked on a series of consultations to assess
economic analytical tools to support vaccine introduc-
tion decisions for pneumococcal, rotavirus and human
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vaccine is undergoing pivotal phase 3 evaluation, WHO
is evaluating impact models that can inform decisions
about the use of combinations of antimalarial interven-
tions. The objectives of these assessments are to provide
decision makers with a menu of existing CE tools for
vaccines and a transparent overview of their characteris-
tics rather than to recom m e n das i n g l em o d e l .T h e
goals of these consultations are to provide policy makers
in LMICs with information about the feasibility of
applying these models to aid their own decision making,
as well as with guidance for interpreting the results
from these and similar studies. Country-level decision
making for the introduction decisions regarding new
vaccines is a complex process that needs to take into
account several factors, such as local information on
patterns of disease transmission, effective coverage and
costs per dose, as these parameters are often the ones
that drive the outcomes of the CEA. In addition, the
characteristics of the healthcare system and issues perti-
nent to financing, affordability and sustainability should
be important elements in the decision-making process.
Moreover, decision makers often experience substantial
pressure from many stakeholders and “vaccine advo-
cates” who contribute to the interpretation of the avail-
able evidence. The conclusions of the WHO
consultations to assess the vaccine economic analytical
tools mentioned above led us to argue that relying on
CEA results from only a single modelling exercise is not
desirable [4-6]. We also reiterate that conducting sensi-
tivity analyses is critical to comprehending the model-
ling and CEA outcomes. After a critical review of the
outcomes of these consultations, the WHO Quantitative
Immunization and Vaccine-Related Research Committee
endorsed these statements [7].
Discussion
F r o map u b l i ch e a l t hp e r s p ective, limited financial
resources should be distributed in a fair and effective
manner aimed at achieving the best possible outcomes.
Decisions on implementing new vaccines in national
immunization programmes should be transparent,
unbiased, comprehensive and based on prespecified and
evidence-based criteria [8].
Decision makers in LMICs reportedly find the meth-
ods used and the interpretation of results from CE stu-
dies complex and therefore challenging to use in the
decision-making process. In many LMICs, there are not
fully functional immunization technical advisory groups
to advise national authorities on decisions to introduce
new vaccines or to adjust existing immunization strate-
gies [9]. Where they are in place, these authorities are
confronted with difficulties in interpreting or adapting
results as part of a context-specific analysis. In many
instances, countries need to carry out their own eco-
nomic analyses, as results from existing studies are not
fully generalizable to their own contexts, owing to large
differences in local factors such as disease epidemiology;
vaccine-specific issues (for example, distribution and
replacement of serotypes); the magnitude of estimated
herd immunity effects, given local immunization strate-
gies and effective coverage; as well as local health care
systems, budgets and vaccination policies [10,11]. Con-
sequently, policy makers often support recommenda-
tions to introduce vaccines in the absence of a
transparent, formally structured and independent review
process. Frequently this is observed in situations in
which there is considerable external pressure from the
general public and those with vested interests [12-14].
Models become more complex if one attempts to evalu-
ate the community-wide and combined effects of inter-
ventions. For instance, pneumococcal and Haemophilus
influenzae type b immunizations need to be assessed in
comparison to or in combination with other possible
interventions, such as community-based treatment, pro-
motion of exclusive breastfeeding and zinc supplementa-
tion [15]. Antimalarial interventions should be assessed
in the context of the options available to national
malaria control programmes [16,17]. Current dose prices
for rotavirus and pneumococcal vaccinations provided
by the Global Alliance for Vaccines and Immunisation
in 2010 were around US$4.00 to US$7.00 compared to
the dollars and cents required for traditional vaccines
such as diphtheria, tetanus and pertussis or measles. As
this may pose serious financial challenges to the budgets
of national immunization programmes in LMICs, policy
makers in those countries welcome donor funds to take
up vaccines in their national vaccine programmes, often
without considering long-term sustainability issues if
donor support fades out.
The series of consultations that WHO conducted in
2009 and 2010 to compare CE tools and models using
standardized data sets from different WHO regions and
predefined vaccine delivery scenarios are useful for sev-
eral reasons [4-6]. Actual tool comparison promotes
transparency. It allows for model structure validation,
provides analysts and decision makers with a more in-
depth view of disease dynamics and offers access to the
assumptions and sources of data used within the various
input parameters. This will allow decision makers to
draw on the estimates from different models and CEAs.
It also will guide future research on appropriate model
structures and will encourage data collection using the
most important model parameters driving CE results.
Comparing uncertainty boundaries around CE results
using different modelling tools will identify evidence
gaps and hence help guide future data collection efforts
(for example, from disease surveillance networks).
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dized data sets and scenarios will facilitate the compari-
son of robustness and clarity of model structures and
assumptions. Better understanding and transparency of
existing decision-making tools and models will focus
efforts and limited resources, in particular in LMICs, on
the generation of better-quality data rather than on
additional, often more complex CE models that suffer
from the same data paucity.
Summary
Economic decision-making tools are an aid that make it
possible to explore the potential impact of various inter-
ventions and policy options. They do not necessarily
provide a final answer to policy questions, but offer
decision makers a structured and logical framework
within which to assess the impact of one or more sce-
narios. Given the inherent complexity of this type of
analysis, tools need to be transparent in terms of model
structure, parameter values, sources of data and valida-
tion process so that the robustness of their results can
be assessed. Using uncertainty analysis throughout the
process of reviewing one or more tools helps to identify
those parameters that will have a greater impact on the
results and therefore on the data collection and synth-
esis priorities which may guide disease surveillance net-
works to promote an integrated and comprehensive
approach to data gathering and analysis in the future. In
order for any CEA to be reliable at the country level,
access to locally relevant, recent and high-quality data is
crucial.
Mathematical models and CEAs should be used as
tools to evaluate the impact of interventions under var-
ious likely scenarios. Their sole use as advocacy tools in
support of a given choice is not adequate. The WHO
recommends that CEAs of introducing a new vaccine
(and the various strategic options) into a national immu-
nization programme be considered before any specific
strategy is implemented. Toward this end, the WHO
has released a vaccine- and immunization-specific guide
on CEA [18,19]. It is recommended that models and
CEAs of vaccines that use locally relevant data and
assumptions are needed to better inform vaccine intro-
duction decisions at the local level, particularly in
LMICs. Capacity strengthening in this area at the local
level is a critical step in promoting the rational use of
these evaluations and tools [12,20].
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